Downregulation of RTN1-C attenuates MPP+-induced neuronal injury through inhibition of mGluR5 pathway in SN4741 cells

被引:2
作者
Chang, Jiang [1 ]
Zhang, Xiao-Le [1 ]
Yu, Hua [1 ]
Chen, Jie [1 ]
机构
[1] Shaanxi Prov Hosp Tradit Chinese Med, Dept Encephalopathy, Xian 710003, Shaanxi, Peoples R China
关键词
Parkinson's disease; RTN1-C; Ca2+ homeostasis; mGluR5; METABOTROPIC GLUTAMATE RECEPTORS; ENDOPLASMIC-RETICULUM; PROTEIN-C; DIFFERENTIATION; MODULATION; ACTIVATION; EXPRESSION; INTERACTS; DISEASE; BRAIN;
D O I
10.1016/j.brainresbull.2018.11.026
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Reticulons (RTNs) are a group of membrane-bound proteins that are dominantly localized to the endoplasmic reticulum (ER). RTN1-C, one isoform of RTNs highly expressed in the brain, has been shown to mediate neuronal injury in cerebral ischemia models. The aim of this study was to investigate the role of RTN1-C in an in vitro model of Parkinson's disease (PD) mimicked by 1-methyl-4-phenylpyridinium (MPP+) treatment in SN4741 cells. We found that MPP+ significantly increased the expression of RTN1-C, with no effect on RTN1-A and RTN1-B. Downregulation of RTN1-C using siRNA (Si-RTN1-C) markedly increased cell viability and inhibited apoptosis induced by MPP+ treatment. The results of western blot showed that downregulation of RTN1-C inhibited the surface expression of metabotropic glutamate receptor 5 (mGluR5) but had no effect on mGluR1. The protective effects of Si-RTN1-C were partially prevented by activating mGluR5, not mGluRl. In addition, the results of Ca2+ imaging showed that downregulation of RTN1-C attenuated intracellular Ca2+ release induced by MPP+, which could be nullified by activation of mGluR5 pathway. In conclusion, our data suggest that downregulation of RTN1-C protects SN4741 cells against MPP+ through mGluR5-mediated preservation of Ca2+ homeostasis. Therefore, RTN1-C might represent a therapeutic target for the treatment of neuronal injury in experimental PD models.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 32 条
[1]   Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems [J].
Alagarsamy, S ;
Marino, MJ ;
Rouse, ST ;
Gereau, RW ;
Heinemann, SF ;
Conn, PJ .
NATURE NEUROSCIENCE, 1999, 2 (03) :234-240
[2]  
Amoral Kaidery N, 2018, NEUROCHEM INT
[3]   Calcium signaling in Parkinson's disease [J].
Cali, Tito ;
Ottolini, Denis ;
Brini, Marisa .
CELL AND TISSUE RESEARCH, 2014, 357 (02) :439-454
[4]  
Charvin D, 2018, NAT REV DRUG DISCOV, V17, P804, DOI 10.1038/nrd.2018.136
[5]   Sirt1-Sirt3 axis regulates human blood-brain barrier permeability in response to ischemia [J].
Chen, Tao ;
Dai, Shu-Hui ;
Li, Xia ;
Luo, Peng ;
Zhu, Jie ;
Wang, Yu -Hai ;
Fei, Zhou ;
Jiang, Xiao-Fan .
REDOX BIOLOGY, 2018, 14 :229-236
[6]   Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease [J].
Chen, Tao ;
Yang, Yue-fan ;
Luo, Peng ;
Liu, Wei ;
Dai, Shu-hui ;
Zheng, Xin-rui ;
Fei, Zhou ;
Jiang, Xiao-fan .
CELLULAR SIGNALLING, 2013, 25 (12) :2863-2870
[7]   Down-regulation of Homer1b/c attenuates glutamate-mediated excitotoxicity through endoplasmic reticulum and mitochondria pathways in rat cortical neurons [J].
Chen, Tao ;
Fei, Fei ;
Jiang, Xiao-fan ;
Zhang, Lei ;
Qu, Yan ;
Huo, Kai ;
Fei, Zhou .
FREE RADICAL BIOLOGY AND MEDICINE, 2012, 52 (01) :208-217
[8]   Reticulon-1C acts as a molecular switch between endoplasmic reticulum stress and genotoxic cell death pathway in human neuroblastoma cells [J].
Di Sano, Federica ;
Fazi, Barbara ;
Tufi, Roberta ;
Nardacci, Roberta ;
Piacentini, Mauro .
JOURNAL OF NEUROCHEMISTRY, 2007, 102 (02) :345-353
[9]   Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 [J].
Dorsey, E. R. ;
Constantinescu, R. ;
Thompson, J. P. ;
Biglan, K. M. ;
Holloway, R. G. ;
Kieburtz, K. ;
Marshall, F. J. ;
Ravina, B. M. ;
Schifitto, G. ;
Siderowf, A. ;
Tanner, C. M. .
NEUROLOGY, 2007, 68 (05) :384-386
[10]   Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets [J].
Enz, Ralf .
CURRENT DRUG TARGETS, 2012, 13 (01) :145-156